可持续性理论视角下的县级医院实施基本药物制度效果研究
|
摘要
研究目的
本研究在总结国外先进经验和进行深入政策梳理的基础上，设计调查工具并进行现场调查，了解目前基本药物制度在县级医院的实施现状，掌握实施与未实施―零差率‖销售的医院之间的效果差异，分析影响实施效果的机构、医生、患者以及外部配套政策等各方面因素，通过理论分析和实践调研两方面给予基本药物制度在县级医院取得有效的可持续的效果提供政策建议。
材料与方法
(1)文献分析
以卫生政策可持续性理论为贯穿整个研究的主线，从基本药物制度实施效果及其影响因素两方面，对比国外的先进经验，总结国内目前制度实施中存在的问题。
(2)现场调查资料分析
确定县医院最常见8个病种的36种基本药物作为调查药品目录。选择安徽省内合肥市、芜湖市和马鞍山市的10家县级医院作为调查现场。调查结果指标包括机构药品可获得性、可负担性和合理用药。使用SPSS16.0对机构、医生、患者的基本情况以及处方/病历质量指标进行描述性分析；计数资料使用率或构成比表示，采用卡方检验或Fisher确切概率法进行比较，检验水准ɑ=0.05；医生合理用药处方质量指标以及患者基本药物相关知识知晓水平及态度影响因素采用多重线性回归分析。
研究结果
(1)总体情况
共调查10家县医院，其中5家实行了基本药物―零差率‖销售。调取并统计4个门诊病种处方5044份、4个住院病种2640份病历，医生行为处方5460份。共计有578名具有处方权的医生和1064名患者完成调查问卷。
(2)基本药物可获得性
实施―零差率‖销售的医院基本药物存储率为85.87%，未实施―零差率‖销售的医院为89.22%，两者之间的差异有统计学意义（P=0.038）。
(3)基本药物的可负担性
实施基本药物―零差率‖销售的县医院平均有30%的药品不可负担；未实施的县医院平均37.22%的药品为不可负担。
(4)机构合理用药
实施基本药物―零差率‖销售的医院与未实施―零差率‖销售的医院相比，患者所取到的药品标示清楚比例较高（分别为46.6%和37.3%）、患者知道服药剂量的比例较低（分别为75.0%和78.8%）、患者的平均接诊时间和配药时间较长，处方药品数量和实际配药数量均较高。
(5)医生合理用药
实施基本药物―零差率‖销售的医院与未实施―零差率‖销售的医院相比，门诊病种处方中的平均药品数量较多（分别为2.34和2.3），通用名比例较低（分别为96.8%和99.1%）、抗生素比例较高（分别为21.2%和18.26%）、基本药物比例较高（分别为38.8%和34.03%）；住院病种的抗生素比例较高（分别为21.37%和20.0%），注射剂比例较高（分别为87.58%和85.73%），基本药物比例较高（分别为65.5%和57.7%）。
(6)患者基本药物知晓程度和态度
1064名患者中，听说过―基本药物‖概念的仅有159人（14.9%），其知识来源主要是：医务人员（45.3%），电视（39.6%）和网络（27%）；19.2%的患者表示不愿意使用基本药物，原因主要为不信赖其疗效（87.7%），认为质量难以保证（26.5%）。患者的年龄、职业、文化程度、医保类型等与其基本药物知识了解程度以及使用意愿不相关。
(7)医生合理用药影响因素
影响医生处方药品数量的因素有学历和专业；影响处方通用名使用比例的因素有学历、专业、教育培训经历及对国家基本药物制度的态度；影响处方抗生素使用比例的因素有年龄、学历、专业；影响处方注射剂使用比例的因素有学历和专业；影响处方基本药物使用比例的因素有学历、专业和药品专业知识。
研究结论
(1)县级医院基本药物的可获得性总体上较高，但实施基本药物―零差率‖销售的县医院的可获得性反而低于未实施的县医院。
(2)实施基本药物―零差率‖销售的县医院药品可负担性要明显优于未实施基本药物―零差率‖销售的县医院。
(3)实施基本药物―零差率‖销售的县医院与未实施的县医院处方/病历相比，处方药品数量偏高，通用名使用比例偏低，抗生素和注射剂使用比例偏高，基本药物使用比例较高。
(4)医生的年龄、学历、专业、接受的教育培训经历、对药品的专业知识了解程度等因素均会对其处方的合理性产生影响。
(5)基本药物制度对于广大人民群众的宣传教育力度不够，方式单一。
(6)政府缺乏有效的监管，补偿不到位；机构内部未形成竞争性的人事制度，无法产生激励作用。
政策建议
(1)建立科学适用的县级医院基本药物目录
统一遴选标准，以―适用、经济、有效‖为原则；遴选参与主体构成公开透明，综合考虑；地方增补目录考虑地区经济社会发展水平及健康问题的差异性。
(2)合理定价，规范配送，确保基本药物的可及性
建立平衡定价机制，在确保低价的同时要保证生产企业的积极性；集中招标采购过程中做到价格和质量的平衡；尝试中标企业直接负责药品配送，减少中间环节。
(3)转变医院管理理念，优先配备并使用基本药物
改变―以药养医‖观念，加强医院精细化管理，提高医院运行效率，制定促进基本药物优先合理使用具体实施办法及措施、明确本单位基本药物配备使用比例、培训考核方案等；加大对医务人员处方行为的监督。
(4)加强培训，规范医生处方行为
加强对医学生和医务人员的教育培训考核；建立健全激励约束机制，成立处方管理部门，对医生处方行为进行分类和限制；加大医生处方抽查、点评力度，明确奖惩措施并真正落实。建立起体现医务人员劳务价值的薪酬制度、竞争性的人事制度和激励性的分配制度，提高合理用药。
(5)落实政府办医责任，构建多渠道的补偿机制
建立新型财政补偿制度，落实政府办医主要责任的同时，形成医疗保险基金购买服务补偿、医院服务价格补偿等多元化的渠道。
(6)优化基本药物报销政策，发挥医疗保险的杠杆作用
社会医保部门参与基本药物制度各环节制定；基本药物取消起付线，有条件的地区实行门诊基本药物100%报销；住院病种实行总额预付和按病种付费方式。
创新与不足
(1)创新在国内卫生政策研究领域首次将卫生项目的可持续性理论引入基本药物制度在县级医院的实施效果之中；在分析合理用药指标与医生方面影响因素过程中，能够做到将医生的处方与其问卷一一对应，弥补了现有的相关研究中两者分开的缺陷；从理论和实证两个角度为基本药物制度在县级医院实施效果的分析提供依据，将实施的机构和未实施的机构进行对比，不仅增强了结果的可信性，更能从比较分析中得出实施效果的核心影响因素。
(2)不足
实证调查只选取安徽省内的三个地市作为现场，结果在一定程度上无法反映全国的现状，在接下来的研究中，可以考虑做多个省份之间的对比；由于本研究从制度本身、实施制度的主体、外部配套政策三个方面，较为全面地囊括了制度各方面可能的影响因素，针对基本药物制度核心的医疗保险和政府补偿两方面内容未进行深入透彻的分析，今后的研究需要在此基础上，对每一点进行深挖掘。
[Aim] Study tools were designed based on summarizing foreign advanced experiences andreviewing domestic and foreign drug policies. Field investigation were carried out in Anhuiprovince so as to understand current implementation situation of essential medicine systemin county hospitals and observe the differences of policy effect between those hospitals thatexecute―zero markup‖policy and those not. Influence factors of essential medicine policyimplementation effect were analyzed from hospital management, doctors, patients andexternal supporting policies aspects. Based on the results of theoretical analysis and fieldsurvey, policy suggestions were present in order to help essential medicine policy toachieve sustainable effect in Chinese county level hospitals.
[Materials and Methods]
(1) Literature Reviewing
Sustainability of health policy theory was the mainline that run through the wholeresearch. Implementation effect of essential medicine policy and its influencing factorswere compared to the advanced experience of foreign countries. We summed up thedomestic problems in the implementation of the policy.
(2) Field survey data analysis
36drugs that treat8common disease entities in county hospitals were selected asSurvey Drug Catalogue. Ten county hospitals in Hefei, Wuhu and Ma Anshan cities ofAnhui province were selected as research sites. Outcome indicators include availability,affordability and rational drug use. SPSS16.0was used to complete data statistic analysis.Descriptive analysis was used to describe fundamental status of hospitals, doctors andpatients. Proportion or constituent ratio was used to express enumeration data, chi-squaretest or Fisher exact probability was used to make a comparison, and α=0.05was set as thesignificant level. Influence factor of rational drug use of doctors was analyzed by multiplelinear regressions.
[Results]
(1) General situation
Ten county hospitals were investigated, and5of them have implemented the―zero markup policy‖of essential medicines.5044disease entities prescriptions wereselected and counted (including hypertension, diabetes, pelvic inflammatory disease andchildren diarrhea), as well as2640medical records (including cerebral infarction,pneumonia in children, gallstone, cesarean section), and5640doctors‘prescriptions werealso included. A total of578prescribers and1064patients completed the questionnaire.
(2) Availability of essential medicines
The average storage proportion in county hospitals which implemented the―zero markup policy‖was85.87%, and the proportion in those not was89.22%. And thedifference between the two had statistical significance (P=0.038).
(3) Affordability of essential medicines
The county hospitals which implemented the―zero markup policy‖of essentialmedicines had a proportion of30%medicines unaffordable, and those not had a proportionof37.22%medicines unaffordable.
(4) Institutions‘rational use of medicines
The proportion of the medicines with clearly marked patients got from the hospitalpharmacies in the hospitals which implemented the―zero markup policy‖was higher thanthose not (46.6%and37.3%respectively). The proportion of patients who were familiarwith the medication doze in the hospitals which implemented the―zero markup policy‖waslower than those not (75.0%and78.8%respectively). Compared with the hospitals whichhaven‘t implemented the―zero markup policy‖, the average treatment time and dispensingtime of the patients in hospitals which implemented the policy was longer, the numbers ofprescription drugs and the actual numbers of dispensing were also higher.
(5)Doctors‘rational use of medicines
Compared the hospitals which implemented the―zero markup policy‖with those not,the average drug numbers was higher (2.34and2.3respectively), the proportion of generalname used was lower (96.8%and99.1%respectively), the average antibiotics proportionwas higher (21.2%and18.26%respectively), and the proportion of essential medicines washigher (38.8%and34.03%respectively) for those four outpatient disease entities.
Compared with hospitals which haven‘t implemented the―zero markup policy‖, theantibiotics proportion in hospitals which implemented the policy was higher (21.37%and20.00%respectively), the proportion of injections was higher (87.58%and85.73%respectively), and the proportion of essential medicines was higher (65.5%and57.7%respectively) for those four inpatient disease entities.(6) Patients‘awareness and attitudes towards essential medicines
Of all the1064patients, only159(14.9%) have heard of―essential medicines‖, and thetop three sources of knowledge was medical staff (45.3%), television (39.6%) and thenetwork (27.0%) respectively.19.2%of the patients showed that they were unwilling to usethe essential medicines if doctors recommended, and the reason was mainly not trust thetherapeutic effectiveness of essential medicines(87.7%), or the quality of essentialmedicines was difficult to guarantee(26.5%). There was no relationship between thepatients‘demographic characteristics such as age, job, education degree, health insurancetypes and their awareness of essential medicines and willingness to use essential medicines.
(7) Influencing factors of rational drug use among doctors
The drug number of doctor‘s prescriptions would influenced by their degree andprofession; the proportion of general name used in doctor‘s prescriptions would influencedby their degree, profession, educational and training experiences and their attitudes towardsessential medicine policy. Doctors‘age, degree and profession were the influencing factorsof the antibiotics proportion. The proportion of injections used in the prescriptions wasaffected by doctors‘degree and profession. Furthermore, doctors‘degree, profession andpharmaceutical expertise would influence the proportion of essential medicines in theprescriptions.
[Conclusions]
(1) Generally the availability of essential medicine was high in county hospitals. In countyhospitals that implemented―zero markup policy‖, the availability of essential medicine waslower than those not implement the policy.
(2) Affordability in hospitals that implement―zero markup policy‖was obviously betterthose not implement the policy.
(3) Compared to the hospitals that not implement the―zero markup policy‖, in hospitalswhich implement the policy, the drug number was higher, the percentages of drugs prescribed by generic name was lower, the antibiotic, injection and essential drugproportion were higher.
(4) Doctor's age, degree, profession, educational and training experience, professional drugknowledge could affect the rationality of their prescription.
(5) The publicity degree of essential medicine policy was inadequate for patients.(6)The government did not carried out stringent regulatory on hospitals and thecompensation to hospitals was far enough. County hospitals haven‘t established acompetitive employment mechanism so there was no incentive for doctors to use essentialmedicines.
[Suggestions]
(1) Establish a scientific and practicable essential medicine list for county hospitals.
Unify the drug selection standards and adhere to the principle of―suitable, economicaland effective‖; ensure the openness and comprehensiveness of the selection body; take areadifferences into consideration.
(2) Ensure the timely distribution of essential medicine for county hospitals.
Set up a balanced pricing mechanism and ensure the enthusiasm of medicinemanufactures; realize the balance between low price and high quality in the process ofcentralized bid procurement; manufactures who win the bidding can take the responsibilityof distribution so as to cut down intermediate links.
(3) County level hospitals change concept and use essential medicine as first choice.
County level hospitals should change the idea of "drug-maintaining-medicine‖;reinforce delicacy management and enhance operating efficiency; draw up measures topromote the preferential use of essential medicine; define the essential medicine allocateratio and assessment programs for doctors; strengthen the prescription check andsupervision among doctors.
(4) Enforce training and standardize prescription pattern among doctors.
Reinforce education and examination of relevant knowledge on essential medicineamong doctors， perfect motivation and restriction mechanism; establish prescriptionmanagement department and impose restrictions on their prescription pattern; intensifyprescription selective inspection and comment; set up a remuneration system that canreflect the labor value of doctors; build a competitive personnel system and an inspirational allocation system.
(5) Government commit to their responsibility in the policy.
A new type of financial compensation mechanism should be built. Diversifiedcompensation channel should be formed such as health insurance fund and hospital riskfund compensation, and establish.
(6) Optimize the reimbursement policy and bring the role of health insurance departmentsinto play.
Pay line for essential drugs could be cancelled and in areas where conditions permitthe100%reimbursement for hospital medication drugs can be implemented. In countyhospital, the DRGs prepaid system for inpatient can be carried out.
[Innovation and deficiency]
(1) Innovation
It‘s the first time to introduce health program sustainability theory into the study ofessential medicine policy implementation effect in county hospitals both home and aboard.There was no study concerning the corresponding relationship between a doctor‘s conditionand his or her prescription by now. We integrated surveys on doctors with their prescriptionrecords for the first time. The basis for the analysis of essential medicine policyimplementation effect from both theoretical and empirical aspects, thus enhanced thecredibility of research results, also get core influence factors by comparative analysis.
(2) Deficiency
Only three cities in Anhui province were selected as field test sites, so the results maybe not able to reflect the whole status quo in the whole country. So comparisons betweendifferent provinces should be made in the following studies. Our study included all thepossible influence factors comprehensively from three aspects (policy itself, main policybodies and external supporting policies). However, thorough analysis on medical insuranceand government compensation, two core elements of essential medicine policy, haven‘tbeen done, and this deficiency should be remedied in the future studies.
本研究在总结国外先进经验和进行深入政策梳理的基础上，设计调查工具并进行现场调查，了解目前基本药物制度在县级医院的实施现状，掌握实施与未实施―零差率‖销售的医院之间的效果差异，分析影响实施效果的机构、医生、患者以及外部配套政策等各方面因素，通过理论分析和实践调研两方面给予基本药物制度在县级医院取得有效的可持续的效果提供政策建议。
材料与方法
(1)文献分析
以卫生政策可持续性理论为贯穿整个研究的主线，从基本药物制度实施效果及其影响因素两方面，对比国外的先进经验，总结国内目前制度实施中存在的问题。
(2)现场调查资料分析
确定县医院最常见8个病种的36种基本药物作为调查药品目录。选择安徽省内合肥市、芜湖市和马鞍山市的10家县级医院作为调查现场。调查结果指标包括机构药品可获得性、可负担性和合理用药。使用SPSS16.0对机构、医生、患者的基本情况以及处方/病历质量指标进行描述性分析；计数资料使用率或构成比表示，采用卡方检验或Fisher确切概率法进行比较，检验水准ɑ=0.05；医生合理用药处方质量指标以及患者基本药物相关知识知晓水平及态度影响因素采用多重线性回归分析。
研究结果
(1)总体情况
共调查10家县医院，其中5家实行了基本药物―零差率‖销售。调取并统计4个门诊病种处方5044份、4个住院病种2640份病历，医生行为处方5460份。共计有578名具有处方权的医生和1064名患者完成调查问卷。
(2)基本药物可获得性
实施―零差率‖销售的医院基本药物存储率为85.87%，未实施―零差率‖销售的医院为89.22%，两者之间的差异有统计学意义（P=0.038）。
(3)基本药物的可负担性
实施基本药物―零差率‖销售的县医院平均有30%的药品不可负担；未实施的县医院平均37.22%的药品为不可负担。
(4)机构合理用药
实施基本药物―零差率‖销售的医院与未实施―零差率‖销售的医院相比，患者所取到的药品标示清楚比例较高（分别为46.6%和37.3%）、患者知道服药剂量的比例较低（分别为75.0%和78.8%）、患者的平均接诊时间和配药时间较长，处方药品数量和实际配药数量均较高。
(5)医生合理用药
实施基本药物―零差率‖销售的医院与未实施―零差率‖销售的医院相比，门诊病种处方中的平均药品数量较多（分别为2.34和2.3），通用名比例较低（分别为96.8%和99.1%）、抗生素比例较高（分别为21.2%和18.26%）、基本药物比例较高（分别为38.8%和34.03%）；住院病种的抗生素比例较高（分别为21.37%和20.0%），注射剂比例较高（分别为87.58%和85.73%），基本药物比例较高（分别为65.5%和57.7%）。
(6)患者基本药物知晓程度和态度
1064名患者中，听说过―基本药物‖概念的仅有159人（14.9%），其知识来源主要是：医务人员（45.3%），电视（39.6%）和网络（27%）；19.2%的患者表示不愿意使用基本药物，原因主要为不信赖其疗效（87.7%），认为质量难以保证（26.5%）。患者的年龄、职业、文化程度、医保类型等与其基本药物知识了解程度以及使用意愿不相关。
(7)医生合理用药影响因素
影响医生处方药品数量的因素有学历和专业；影响处方通用名使用比例的因素有学历、专业、教育培训经历及对国家基本药物制度的态度；影响处方抗生素使用比例的因素有年龄、学历、专业；影响处方注射剂使用比例的因素有学历和专业；影响处方基本药物使用比例的因素有学历、专业和药品专业知识。
研究结论
(1)县级医院基本药物的可获得性总体上较高，但实施基本药物―零差率‖销售的县医院的可获得性反而低于未实施的县医院。
(2)实施基本药物―零差率‖销售的县医院药品可负担性要明显优于未实施基本药物―零差率‖销售的县医院。
(3)实施基本药物―零差率‖销售的县医院与未实施的县医院处方/病历相比，处方药品数量偏高，通用名使用比例偏低，抗生素和注射剂使用比例偏高，基本药物使用比例较高。
(4)医生的年龄、学历、专业、接受的教育培训经历、对药品的专业知识了解程度等因素均会对其处方的合理性产生影响。
(5)基本药物制度对于广大人民群众的宣传教育力度不够，方式单一。
(6)政府缺乏有效的监管，补偿不到位；机构内部未形成竞争性的人事制度，无法产生激励作用。
政策建议
(1)建立科学适用的县级医院基本药物目录
统一遴选标准，以―适用、经济、有效‖为原则；遴选参与主体构成公开透明，综合考虑；地方增补目录考虑地区经济社会发展水平及健康问题的差异性。
(2)合理定价，规范配送，确保基本药物的可及性
建立平衡定价机制，在确保低价的同时要保证生产企业的积极性；集中招标采购过程中做到价格和质量的平衡；尝试中标企业直接负责药品配送，减少中间环节。
(3)转变医院管理理念，优先配备并使用基本药物
改变―以药养医‖观念，加强医院精细化管理，提高医院运行效率，制定促进基本药物优先合理使用具体实施办法及措施、明确本单位基本药物配备使用比例、培训考核方案等；加大对医务人员处方行为的监督。
(4)加强培训，规范医生处方行为
加强对医学生和医务人员的教育培训考核；建立健全激励约束机制，成立处方管理部门，对医生处方行为进行分类和限制；加大医生处方抽查、点评力度，明确奖惩措施并真正落实。建立起体现医务人员劳务价值的薪酬制度、竞争性的人事制度和激励性的分配制度，提高合理用药。
(5)落实政府办医责任，构建多渠道的补偿机制
建立新型财政补偿制度，落实政府办医主要责任的同时，形成医疗保险基金购买服务补偿、医院服务价格补偿等多元化的渠道。
(6)优化基本药物报销政策，发挥医疗保险的杠杆作用
社会医保部门参与基本药物制度各环节制定；基本药物取消起付线，有条件的地区实行门诊基本药物100%报销；住院病种实行总额预付和按病种付费方式。
创新与不足
(1)创新在国内卫生政策研究领域首次将卫生项目的可持续性理论引入基本药物制度在县级医院的实施效果之中；在分析合理用药指标与医生方面影响因素过程中，能够做到将医生的处方与其问卷一一对应，弥补了现有的相关研究中两者分开的缺陷；从理论和实证两个角度为基本药物制度在县级医院实施效果的分析提供依据，将实施的机构和未实施的机构进行对比，不仅增强了结果的可信性，更能从比较分析中得出实施效果的核心影响因素。
(2)不足
实证调查只选取安徽省内的三个地市作为现场，结果在一定程度上无法反映全国的现状，在接下来的研究中，可以考虑做多个省份之间的对比；由于本研究从制度本身、实施制度的主体、外部配套政策三个方面，较为全面地囊括了制度各方面可能的影响因素，针对基本药物制度核心的医疗保险和政府补偿两方面内容未进行深入透彻的分析，今后的研究需要在此基础上，对每一点进行深挖掘。
[Aim] Study tools were designed based on summarizing foreign advanced experiences andreviewing domestic and foreign drug policies. Field investigation were carried out in Anhuiprovince so as to understand current implementation situation of essential medicine systemin county hospitals and observe the differences of policy effect between those hospitals thatexecute―zero markup‖policy and those not. Influence factors of essential medicine policyimplementation effect were analyzed from hospital management, doctors, patients andexternal supporting policies aspects. Based on the results of theoretical analysis and fieldsurvey, policy suggestions were present in order to help essential medicine policy toachieve sustainable effect in Chinese county level hospitals.
[Materials and Methods]
(1) Literature Reviewing
Sustainability of health policy theory was the mainline that run through the wholeresearch. Implementation effect of essential medicine policy and its influencing factorswere compared to the advanced experience of foreign countries. We summed up thedomestic problems in the implementation of the policy.
(2) Field survey data analysis
36drugs that treat8common disease entities in county hospitals were selected asSurvey Drug Catalogue. Ten county hospitals in Hefei, Wuhu and Ma Anshan cities ofAnhui province were selected as research sites. Outcome indicators include availability,affordability and rational drug use. SPSS16.0was used to complete data statistic analysis.Descriptive analysis was used to describe fundamental status of hospitals, doctors andpatients. Proportion or constituent ratio was used to express enumeration data, chi-squaretest or Fisher exact probability was used to make a comparison, and α=0.05was set as thesignificant level. Influence factor of rational drug use of doctors was analyzed by multiplelinear regressions.
[Results]
(1) General situation
Ten county hospitals were investigated, and5of them have implemented the―zero markup policy‖of essential medicines.5044disease entities prescriptions wereselected and counted (including hypertension, diabetes, pelvic inflammatory disease andchildren diarrhea), as well as2640medical records (including cerebral infarction,pneumonia in children, gallstone, cesarean section), and5640doctors‘prescriptions werealso included. A total of578prescribers and1064patients completed the questionnaire.
(2) Availability of essential medicines
The average storage proportion in county hospitals which implemented the―zero markup policy‖was85.87%, and the proportion in those not was89.22%. And thedifference between the two had statistical significance (P=0.038).
(3) Affordability of essential medicines
The county hospitals which implemented the―zero markup policy‖of essentialmedicines had a proportion of30%medicines unaffordable, and those not had a proportionof37.22%medicines unaffordable.
(4) Institutions‘rational use of medicines
The proportion of the medicines with clearly marked patients got from the hospitalpharmacies in the hospitals which implemented the―zero markup policy‖was higher thanthose not (46.6%and37.3%respectively). The proportion of patients who were familiarwith the medication doze in the hospitals which implemented the―zero markup policy‖waslower than those not (75.0%and78.8%respectively). Compared with the hospitals whichhaven‘t implemented the―zero markup policy‖, the average treatment time and dispensingtime of the patients in hospitals which implemented the policy was longer, the numbers ofprescription drugs and the actual numbers of dispensing were also higher.
(5)Doctors‘rational use of medicines
Compared the hospitals which implemented the―zero markup policy‖with those not,the average drug numbers was higher (2.34and2.3respectively), the proportion of generalname used was lower (96.8%and99.1%respectively), the average antibiotics proportionwas higher (21.2%and18.26%respectively), and the proportion of essential medicines washigher (38.8%and34.03%respectively) for those four outpatient disease entities.
Compared with hospitals which haven‘t implemented the―zero markup policy‖, theantibiotics proportion in hospitals which implemented the policy was higher (21.37%and20.00%respectively), the proportion of injections was higher (87.58%and85.73%respectively), and the proportion of essential medicines was higher (65.5%and57.7%respectively) for those four inpatient disease entities.(6) Patients‘awareness and attitudes towards essential medicines
Of all the1064patients, only159(14.9%) have heard of―essential medicines‖, and thetop three sources of knowledge was medical staff (45.3%), television (39.6%) and thenetwork (27.0%) respectively.19.2%of the patients showed that they were unwilling to usethe essential medicines if doctors recommended, and the reason was mainly not trust thetherapeutic effectiveness of essential medicines(87.7%), or the quality of essentialmedicines was difficult to guarantee(26.5%). There was no relationship between thepatients‘demographic characteristics such as age, job, education degree, health insurancetypes and their awareness of essential medicines and willingness to use essential medicines.
(7) Influencing factors of rational drug use among doctors
The drug number of doctor‘s prescriptions would influenced by their degree andprofession; the proportion of general name used in doctor‘s prescriptions would influencedby their degree, profession, educational and training experiences and their attitudes towardsessential medicine policy. Doctors‘age, degree and profession were the influencing factorsof the antibiotics proportion. The proportion of injections used in the prescriptions wasaffected by doctors‘degree and profession. Furthermore, doctors‘degree, profession andpharmaceutical expertise would influence the proportion of essential medicines in theprescriptions.
[Conclusions]
(1) Generally the availability of essential medicine was high in county hospitals. In countyhospitals that implemented―zero markup policy‖, the availability of essential medicine waslower than those not implement the policy.
(2) Affordability in hospitals that implement―zero markup policy‖was obviously betterthose not implement the policy.
(3) Compared to the hospitals that not implement the―zero markup policy‖, in hospitalswhich implement the policy, the drug number was higher, the percentages of drugs prescribed by generic name was lower, the antibiotic, injection and essential drugproportion were higher.
(4) Doctor's age, degree, profession, educational and training experience, professional drugknowledge could affect the rationality of their prescription.
(5) The publicity degree of essential medicine policy was inadequate for patients.(6)The government did not carried out stringent regulatory on hospitals and thecompensation to hospitals was far enough. County hospitals haven‘t established acompetitive employment mechanism so there was no incentive for doctors to use essentialmedicines.
[Suggestions]
(1) Establish a scientific and practicable essential medicine list for county hospitals.
Unify the drug selection standards and adhere to the principle of―suitable, economicaland effective‖; ensure the openness and comprehensiveness of the selection body; take areadifferences into consideration.
(2) Ensure the timely distribution of essential medicine for county hospitals.
Set up a balanced pricing mechanism and ensure the enthusiasm of medicinemanufactures; realize the balance between low price and high quality in the process ofcentralized bid procurement; manufactures who win the bidding can take the responsibilityof distribution so as to cut down intermediate links.
(3) County level hospitals change concept and use essential medicine as first choice.
County level hospitals should change the idea of "drug-maintaining-medicine‖;reinforce delicacy management and enhance operating efficiency; draw up measures topromote the preferential use of essential medicine; define the essential medicine allocateratio and assessment programs for doctors; strengthen the prescription check andsupervision among doctors.
(4) Enforce training and standardize prescription pattern among doctors.
Reinforce education and examination of relevant knowledge on essential medicineamong doctors， perfect motivation and restriction mechanism; establish prescriptionmanagement department and impose restrictions on their prescription pattern; intensifyprescription selective inspection and comment; set up a remuneration system that canreflect the labor value of doctors; build a competitive personnel system and an inspirational allocation system.
(5) Government commit to their responsibility in the policy.
A new type of financial compensation mechanism should be built. Diversifiedcompensation channel should be formed such as health insurance fund and hospital riskfund compensation, and establish.
(6) Optimize the reimbursement policy and bring the role of health insurance departmentsinto play.
Pay line for essential drugs could be cancelled and in areas where conditions permitthe100%reimbursement for hospital medication drugs can be implemented. In countyhospital, the DRGs prepaid system for inpatient can be carried out.
[Innovation and deficiency]
(1) Innovation
It‘s the first time to introduce health program sustainability theory into the study ofessential medicine policy implementation effect in county hospitals both home and aboard.There was no study concerning the corresponding relationship between a doctor‘s conditionand his or her prescription by now. We integrated surveys on doctors with their prescriptionrecords for the first time. The basis for the analysis of essential medicine policyimplementation effect from both theoretical and empirical aspects, thus enhanced thecredibility of research results, also get core influence factors by comparative analysis.
(2) Deficiency
Only three cities in Anhui province were selected as field test sites, so the results maybe not able to reflect the whole status quo in the whole country. So comparisons betweendifferent provinces should be made in the following studies. Our study included all thepossible influence factors comprehensively from three aspects (policy itself, main policybodies and external supporting policies). However, thorough analysis on medical insuranceand government compensation, two core elements of essential medicine policy, haven‘tbeen done, and this deficiency should be remedied in the future studies.
引文
[1]Quick J D, Hogerzeil H V, Velasquez G, etal. Perspectives: Twenty-five years of essentialmedicines [N]. Bulletin of the World Health Organization,2002,80(11):913-914.
[2]WHO.The selection and use of essential drugs: report of a WHO expercommittee [M].(Tech Rep Ser WHO no.914). Geneva: World Health Organization，2003.
[2]WHO. The rational use of drugs: report. Geneva: World Health Organization,1987.
[4]WHO. WHO Policy Perspectives on Medicines, Series No4-The Selection of EssentialMedicines [M]. Geneva,2002.
[5]WHO. The rational use of drugs: report. Geneva: World Health Organization,1987.
[6]Availability. Wikipedia.24November2012.http://en.wikipedia.org/wiki/Availability.
[7]WHO. Indicators for monitoring national drug policies. A practical manual. Secondedition [M]. Geneva,2000.
[8]WHO. How to investigate drug use in health facilities-----Selected drug useindicators [M]. Action programme on essential drugs.1993.
[9]Eric G Sarriot，Peter J. Winch， Leo J Ryan. A methodological approach and frameworkfor sustainability assessment in NGO-implemented primary health care programs [J]. Int JHealth Planning Mgmt2004;19:23–41.
[10]Eric G Sarriot，Peter J Winch，Leo J Ryan. Qualitative research to make practical senseof sustainability in primary health care projects implemented by non-governmentalorganizations [J]. Int J Health Planning Mgmt2004;19:3–22.
[11]Bossert TJ. Can they get along without us? Sustainability of donor-supported healthprojects in Central America and Africa. Soc Sic med1990,30:1015-1023
[12]Lafond AK.1995. Improving the quality of investment in health: lessons onsustainability. Health Policy Plan10:63–76.
[13]Mona C. Shediac-Rizkallah， Lee R. Bone. Planning for the sustainability ofcommunity-based health programs: conceptual frameworks and future directions forresearch, practice and policy[J]. Health Education Research： Vol.13. no. l1998：87-10.
[14]Alice Yang, Paul E. Farmer, Anita M. Mcgahan. Sustainability‘in global health[J].Global Public Health.2010:5(2):129-135.
[15]Eric G. Sarriot, Peter J. Winch. A methodological approach and framework forsustainability assessment in NGO-implemented primary health care programs. Int J HealthPlann Mgmt2004;19:23–41.
[16]彭静,江启成.基本药物制度利益相关者的界定及分析.中国卫生事业管理.2011（5）：348-360.
[17] Joint Commission International Accreditation Standards for Hospital[M]. JointCommission International. Illinois: Joint Commission Resources.2007.
[18]R Roy Chaudhury, R Parameswar, U Gupta, etc. Quality medicines for the poor:experience of the Delhi programme on rational use of drugs[J].Health Policy andPlanning,2005,20(2):124-136
[19]叶露.国家基本药物政策研究[D].上海：复旦大学,2008.
[20]Susan E Tett. A perspective on Australia‘s National Medicine Policy[J].Can J ClinPharmacol,11(1):e28-e38
[21]武瑞雪，刘宝，丁静芳等.基本药物制度实施的国际经验[J].中国药房,2007,18(17):1283-1285.
[22]Anna Hynd, Elizabeth E.Roughead, David B.Preen, etal. The impact of co-paymentincreases on dispensings of government-subsidized medicines in Australia [J].Pharmacoepidemiology and Drug Safety,2008,17:1091-1099.
[23]谢敬敏，张方.关于国家基本药物目录与―医保‖目录、―新农合‖报销目录衔接的思考[J].中国药房,2011,22(16):1443-1445.
[24]焦婷婷，冯泽永.基本药物配置配送环节影响因素分析及对策[J].中国药房.2012，23(16):1474-1476,
[25]欣越.澳大利亚医院管理[J].中国卫生产业,2006,11:84-86.
[26]梁智.澳大利亚医疗制度与改革[J].《国外医学》卫生经济分册,2006,23(3):97-102.
[27]Delia Hendrie and Duncan Boldy. Hospital services and casemix in WesternAustralia[J]. Australia Health Review,2002,25(1):173-188
[28]Lynn Maria Weekes, Colleen Brooks. Drug and Therapeutics Committee inAustralia: expected and actual performance [J]. Br J Clin Pharmacol,1996,42:551-557.
[29]Thailand a country case study: good governance and preventing corruption.WHO.http://www.who.int/features/2010/medicines_thailand/en/index.html.
[30]杨一帆.实施基本药物制度的问题与对策研究.沈阳：沈阳师范大学，2012
[31]邱凯锋，游思平，邓丽华等.国家基本药物在某二级综合医院的应用研究[J].中国医院用药评价与分析,2011,11(10):890-892.
[32]张强，张继海.我院2009年3月-2010年2月基本药物应用情况调查分析[J].中国药房,2010,21(44):4132-4133.
[33]刘朝杰，李伟，姚岚.澳大利亚的社区卫生服务与全科医疗对中国的影响和蕴义[J].中国全科医学,2004,7(21):1545-1550
[34]A.J.Smith, P.McGettigan. Quality use of medicines in the community: theAustralian experience[J].Br J Clin Pharmacol,2000,50:515-519.
[35]L.M.Weekes, J.M.Mackson, M.Fitzgerald, etal. National Prescribing Service: creatingan implementation arm for national medicines policy [J].British Journal of ClinicalPharmacology,2005,59:112-116.
[36]Constraints on prescribers.http://www.pbs.gov.au/info/about-the-pbs#Constraints_on_prescribers.
[37]What are the restrictions on PBS prescriptions? http://www.pbs.gov.au/info/general/faq.
[38]杨帅.我国基本药物制度实施问题研究[D].南京中医药大学，2011.
[39]刘建美.基于国家基本药物政策的县级医院合理用药现状研究[D].山西医科大学,2011.
[40]邵辉,李士雪,徐凌忠,杨爽.山东省基层医疗机构门诊医生基本药物使用医院影响因素分析[J].中国卫生事业管理,2011(12):904-906.
[41]韩晓亮.基于博弈论的基本药物制度研究[D].黑龙江中医药大学.2010.
[42]What are the current patient fees and charges?http://www.pbs.gov.au/info/about-the-pbs#What_are_the_current_patient_fees_and_charges.
[43]王迪飞.基本药物制度实施中的社会医疗保险干预策略研究[D].华中科技大学，2012.
[44]夏俊，田昕，张新平.基本药物医保报销政策研究[J].医学与社会,2010,23(6):64-66.
[45]WHO/HAI. Measuring medicine prices, av ailability, affordability and pricecomponents2ND EDITION[M]. Switzerland: WHO/HAI,2008:1-181.
[46]Greenhalgh T. Drug prescriptions and self-medication in India, an exploratory survey.Social Science and Medicine.1987(25):307-318.
[47]陈峰,陈光启.医学多元统计分析方法（第二版）[M].北京：中国统计出版社,2007：23.
[48]Wen Chen, Shenglan Tang, Jing Sun. Availability and use of essential medicines inChina: manufacturing, supply, and prescribing in Shandong and Gansu provinces[J]. BMCHealth Services Research.2010,10:211.
[49]Hao Yang, Hassan H Dib, Xinping Zhang. Prices, availability and affordability ofessential medicines in rural areas of Hubei Province, China [J]. Health Policy and Planning.2010;25:219-229.
[50]王思欧,刘洋,管晓东.我国部分地区基本药物价格水平实证研究。中国卫生事业管理.2011（4）：266-268.
[51]叶露,胡善联.上海市基本药物可负担性实证研究[J].中国卫生资源,2008,11(4):195-196.
[52]A Cameron, M Ewen, D Ross-Degnan. Medicine prices, availability, and afordabilityin36developing and middle-income countries: a secondary analysis. Published onlineDecember1,2008DOI:10.1016/S0140-6736(08)61762-6.
[53]Mustafa Z Younis, Samer Hamidi, Dana A Forgione, etal. Rational use effects ofimplementing an essential medicines list in West Bank, Palestinian Territories [J].Pharmacoeconomics Outcomes Res.2009:9(3):243-250.
[54]张新毅，郝瑞东，郝钢.507例门诊处方评价与结果分析[J].中国药物警戒.2010:7（12）:755-757.
[55]龙华,吴红卫,王丹阳等.6000张门诊处方基本指标及合理用药分析[J]. Evaluationand analysis of drug-use in hospitals of China.2009,9(4):280-281.
[56]程海道,陆华,刘滔滔.门诊处方基本指标评价及用药合理性分析[J]. Evaluation andanalysis of drug-use in hospitals of China.2012,12(4):373-375.
[57]Hogerzeil HV, Bimo, Ross-Degnan D, etal. Field tests of rational drug use in twelvedeveloping countries [J]. Lancet1993,4:1408-10.
[58]E. T. Adebayo, N.A. Hussain. Pattern of prescription drug use in Nigerian armyhospitals [J]. Annals of African Medicine.2010:9(3):152-187.
[59]Benjamin Uzochukwu, Obinna Onwujekwe, Cyril Akpala. Effect of theBamako-Initiative drug revolving fund on availability and rational use of essential drugs inprimary health care facilities in south-east Nigeria [J]. Health Policy and Planning;2002:17(4):378-383.
[60]Birna Trap, Ebba Holme Hansen and Hans V Hogerzeil. Prescription habits ofdispensing and non-dispensing doctors in Zimbabwe [J]. Health Policy and Planning;2002:17(3):288-295.
[61]Bounxou Keohavong, Lamphone Syhakhang, Sivong Sengaloundeth,etal. Rational useof drugs: prescribing and dispensing practices at public health facilities in Lao PDR [J].Pharmacoepidemiology and Drug Safety.2006:15:344-347.
[62]K.A. Bashrahil. Indicators of rational drug use and health services in Hadramout,Yemen [J]. Eastern Mediterranean Health Journal.2010,16(2):151-155.
[63]Yacoub M. Irshaid, Mohammed A. Al-Homrany, Anwar A. Hamdi, etal. APharmacoepidemiological study of prescription pattern in outpatient clinics inSouthwestern Saudi Arabia [J]. Saudi Med J2004;25(12):1864-1870.
[64]WHO. Action Programme on Essential Drugs. How to investigate drug use in healthfacilities. World Health Organization, Geneva:1993.1-87.
[65]Flora Haayer. Rational Prescribing and Sources of Information [J], Soc. Sci. Med,1982,16:2017-2023.
[66]Letizia Orzella etal. Physician and patient characteristics associated with prescriptionsand costs of drugs in the Lazio region of Italy [J], Health Policy,2010,95(2-3):236-244.
[67]A. Vallano. E. Montane′. J. M. Arnau.X, Vidal C. Pallares. M. Coll. J. R. Laporte.Medical speciality and pattern of medicines prescription [J]. Eur J Clin Pharmacol (2004)60:725–730.
[68]WHO Policy Perspectives on Medicines. Promoting rational use of medicines: corecomponents, Geneva: WHO;2002.
[69]Hans V Hogerzeil. Promoting rational prescribing: an international perspective [J], Br JPharmac,1995,39:1-6.
[70]Adolfo Figueiras, Isabel Sastre, Juan Jesus Gestal-Otero. Effectiveness of educationalinterventions on the improvement of drug prescription in primary care: a critical literaturereview [J]. Journal of Evaluation in Clinical Practice,2001,7(2):223-241.
[71]于坤,曹建文,傅华等.影响医生处方行为的因素分析[J],中华医院管理杂志,2002,18(2):92-94.
[72]Andersen M,Kragstrup J,Sondergaard J. How conducting a clinical trial affectsphysicians‘guideline adherence and drug preferences [J]. JAMA,2006,295(23):2759-2764.
[73]Melville A. Job satisfaction in General Practice: implications for prescribing. Sot SciMed.1980;4A.495.
[74] Australian Government Department of Health and Ageing. Constraints onprescribers.http://www.pbs.gov.au/info/about-the-pbs#Constraints_on_prescribers
[75]张盛国.完善基本药物制度财政补偿机制[J].中国财政.2010,20:49-50.
[76]WHO/UNICEF. Primary health care: report of the International Conference on PrimaryHealth Care, Alma-Alta, USSR, Sept6–12,1978. Health for all, series1. Geneva: WorldHealth Organization,1978.
[1]Quick J D, Hogerzeil H V, Velasquez G, etal. Perspectives: Twenty-five years ofessential medicines [N]. Bulletin of the World Health Organization,2002,80(11):913-914.
[2]WHO.The selection and use of essential drugs: report of a WHO expertcommittee [M].(Tech Rep Ser WHO no.914). Geneva: World Health Organization，2003.
[3]WHO. The rational use of drugs: report. Geneva: World Health Organization,1987.
[4]WHO. WHO Policy Perspectives on Medicines, Series No4-The Selection ofEssential Medicines [M]. Geneva,2002.
[5]WHO. The selection of essential drugs: report of a WHO expert committee.(TechRep Ser WHO no615). Geneva: World Health Organization,1977.
[6]WHO.WHO Policy Perspectives on Medicines, Series No8-Equitable access toessential medicines: a framework for collective action [M]. Geneva,2004.
[7]WHO. WHO Model list of essential medicines (17thlist). March2011.http://www.who.int/medicines/publications/essentialmedicines/en/index.html
[8]WHO. WHO Model list of essential medicines for children (3thlist). March2011.http://www.who.int/medicines/publications/essentialmedicines/en/index.html
[9]WHO.The selection and use of essential drugs: report of a WHO expert committee[M].(Tech Rep Ser WHO no950).Geneva: World Health Organization，2008
[10]WHO. How to develop and implement a national drug policy—second edition.[M]. Geneva,2001.
[11]WHO. Indicators for monitoring national drug policies. A practical manual.Second edition [M]. Geneva,2000.
[12]WHO. Operational package for assessing monitoring and evaluating countrypharmaceutical situations[M]. Geneva,2007.
[13]WHO. Action Programme on Essential Drugs. How to investigate drug use inhealth facilities—selected drug use indicators[M]. WHO/DAP/INRUD.1993.
[14]WHO/HAI. Medicine prices a new approach to measurement,2003edition.Working draft for field testing and revision[M]. WHO/EDM/PAR/2003.2.
[15]WHO/HAI. Measuring medicine prices, availability, affordablity and pricecomoonents,2NDedition[M]. WHO/PSM/PAR/2008.3.
[16]Cha-oncin Sooksriwong, Worasuda Yoongthong, Siriwat Suwattanapreeda.Medicine prices in Thailand: A result of no medicine pricing policy[J]. Southern MedReview,2009,2(2):10-14.
[17]Babar ZUD, Ibrahim MIM, Singh H. Evaluating drug prices, availability,affordablity and price comoonents: implication for access to drugs in Malaysia.[O/L].2010-08-09.http://www.plos medicine.Org/article/info:doi/10.1371/journal.pmed.0040082.
[18]HaoYang, HassanHDib, MinminZhu. Prices, availability and affordability ofessential medicines in rural areas of Hubei Province, China. Health Policy andPlanning2010,25:219-229.
[19]叶露,胡善联等.上海药品价格水平实证研究[J].中国卫生资源，2008，1（5）：238-240.
[20]A Cameron, M Ewen, D Ross-Degnan. Medicine prices, availability, andaffordability in36developing and middle-income countries: a secondary analysis[O/L].2010-08-09. http//:www.ncbi.nlm.nih.gov/pubmed/19042012.
[21]Douglas Ball. Review Series on Pharmaceutical Pricing Policies andInterventions: Working Paper3: The Regulation of Mark-ups in the PharmaceuticalSupply Chain[M]. WHO/HAI Project on Medicine Prices and Availability. May2011.
[22]Laing R Waning B, Gray A.25years of the WHO essential medicines lists:progress and challenges [J]. Lancet,2003,361(9370):1723-9
[23]MarcusMReidenberg,TomWalley. Commentary: The pros and cons of essentialmedicines for rich countries[J]. BMJ VOLUME32913NOVEMBER2004:1172.
[24]HansVHogerzeil. The concept of essential medicines: lessons for richcountries[J]. BMJ VOLUME32913NOVEMBER2004：1169-1172
[25]Zafar Mirza. Thirty years of essential medicines in primary health care[J].Eastern Mediterranean Health Journal, Vol.14, Special Issue:74-81.
[26]Djékadoum Ndilta. Medicines and Primary health care: challenges and hopes inthe church health systems[J]. Contact n°187–January-May2009:8-13.
[27]Jane Masiga. Medicines and Primary health care: where are we?[J]. Contactn°187–January-May2009:14-17.
[28]孙静. WHO基本药物概念与国家实践[J]. Chinese Journal of Health Policy,January2009, Vol.2No.1:38-46.
[29]武瑞雪,刘宝,丁敬芳.基本药物制度实施的国际经验[J].中国药房.2007:17（18）：1283-1285.
[30]胡善联,张崖冰,叶露.国家基本药物制度研究[J].卫生经济研究.2007，10:3-5.
[31]覃正碧,汪志宏,谭刚等.国家基本药物制度的现状及其完善对策探讨[J].中国药房，2008，19(14):1041-1043.
[32]李锋.关于构建国家基本药物制度的若干思考[J].中国卫生事业管理.2010（7）：456-458.
[33]王强.基本药物流通价值链的经济学研究[D].复旦大学：2010年
[34]李红梅.基本药物制度符合百姓利益，需改变以药养医现象[J].人民网-《人民日报》.2011-11-07. http://health.people.com.cn/GB/16157006.html.
[35]Availability. Wikipedia.24November2012.http://en.wikipedia.org/wiki/Availability
[36]WHO. Indicators for monitoring national drug policies. A practical manual. Secondedition [M]. Geneva,2000.
[37]Quick JD (2003) Essential medicines twenty-fve years on: closing the access gap[J].Health Policy&Planning18,1–3.
[38]Access to Essential Drugs in2Brazilian Cities: A Community-based Evaluation.Marg Gomes de Oliveira Karnikowski; Otávio de Toledo Nóbrega; Janeth de Oliv. Journalof Public Health Policy;2004;25,288-298.
[39]Kotwani A, Ewen M, Dey D et al.(2007) Prices&availability of common medicines atsix sites in India using a standard methodology[J]. Indian Journal of Medical Research125,645.
[40]Saleh K&Ibrahim MI (2005) Are essential medicines in Malaysia accessible,affordable and available[J]? Pharmacy World&Science27,442–446.
[41]Babar ZU, Ibrahim MI, Singh H, Bukahri NI&Creese A (2007) Evaluating drug prices,availability, affordability, and price components: implications for access to drugs inMalaysia[J]. PLoS Medicine Public Library of Science4, e82.
[42]Adbol Majid Cheraghali. Availability, Affordability and prescribing pattern ofmedicines in Sudan. Pharmacy World Science.2009,31:209-215.
[43]Mendis S, Fukino K, Cameron A et al.(2007) The availability and affordability ofselected essential medicines for chronic diseases in six low-and middle-incomecountries[J]. Bulletin of the World Health Organization85,279–288.
[44]Sun Qiang，A Survey of Medicine Prices, Availability, Affordability and PriceComponents in Shandong Province, China， October,2005[O/L].[2010-08-09].http://www.haiweb.org/medicineprices/surveys.php.
[45]Hao Yang, Hassan H Dib, Minmin Zhu. Prices, availability and affordability ofessential medicines in rural areas of Hubei Province, China [J]. Health Policy and Planning2010;25:219–229.
[46]Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio. Access to essential drugs inGuyana: a public health challenge. International Journal of Health Planning andManagement.2010,25:2–16.
[47]Lloyd Matowe. Access to essential drugs in developing countries: A lost battle?American Journal of Health System Pharmacy2004,61:718-721
[48]Michael Nunan，Trevor Duke. Effectiveness of pharmacy interventions in improvingavailability of essential medicines at the primary healthcare level. Tropical Medicine andInternational Health.2011,16:647-658.
[49]Michael Nunan，Trevor Duke. Effectiveness of pharmacy interventions in improvingavailability of essential medicines at the primary healthcare level[J]. Tropical Medicine andInternational Health. volume16no5pp647–658may2011.
[50]李萍，张新平.改善农村地区基本药物可获得性策略研究.华中科技大学.2009.
[51]刘宝,武瑞雪,叶露.论基本药物的可获得性和可及性障碍[J].中国药房.2007,5:1-6.
[52]王力,余苏珍,王素珍.提高我国基本药物可及性的政策措施研究.中国卫生经济.2011，7（30）：25-26.
[53]Benjamn SC Uzochukwn. Effect of the Bamako-Initiative drug revolving fund onavailability and rational use of essential drugs in primary health care facilities in South-eastNigeria. Health policy and Planning.2002,17(4):378-383.
[54]W W Anokbonggo，J W Ogwal-Okeng. Imapct of decentralization on heslth services inUganda: A look at facility utilization, prescribing and availability of essential drugs. EastAfrican Medical Journal.2004,81:2-7.
[55]WHO. Harvard Medical School. Medicine use in primary Care in developing andtransitional countries [M].WHO/EMP/MAR.2009:1.
[56]WHO. Promoting rational use of medicines: core components. WHO PolicyPerspectives on Medicines. Sep.2002.
[57]WHO.基本药物概念与实践-向中国政府提交的政策说明[M].国际合理用药与WHO公报汇编,北京：中国科技出版社,2009:50.
[58]姚岚等.合理用药的国际研究进展[J],中国初级卫生保健,2002,16(3):4-6.
[59]Hans V Hogerzeil.Promoting rational prescribing:an international perspective[J],Br JPharmac,1995,39:1-6.
[60]王跃平等.深圳市福田区社康中心基本药物的配备及使用情况分析[J],中国全科医学,2011,14(7A):2188-2191.
[61]祁金文,马珂,陈农.规范医生处方行为提高合理用药水平[J],中华医院管理杂志,2006,22(12):817-819.
[62]刘玉聪,孙利华,孙倩.国外规范医生处方行为的措施及其对我国的启示[J],中国药业,2010,19(24):9-10.
[63]WHO Policy Perspectives on Medicines.Promoting rational use of medicines:corecomponents,Geneva:WHO;2002.
[64]R Mahajan,NR Singh,J Singh et al.Assessment of Awareness among Clinicians aboutConcepts in Undergraduate Pharmacology Curriculum: A Novel Cross-sectional Study[J],Journal of Young Pharmacists,2010,2(3):301-305.
[65]曾雁冰,杨世民.对基本药物认知及临床应用情况的调查研究[J],中国药事,2008,22(9):756-762.
[66]Geoffrey M.Anderson,Joel Lexchin,Strategies for Improving Prescribing Pratice[J],Can Med Assoc J,1996,154(7):1013-1017.
[67]Adolfo Figueiras,Isabel Sastre,Juan Jesus Gestal-Otero.Effectiveness of educationalinterventions on the improvement of drug prescription in primary care:a critical literaturereview,Journal of Evaluation in Clinacal Practice,2001,7(2):223-241.
[68]Rajiv Mahajan et al.Current scenario of attitude and knowledge of physicians aboutrational prescription: A novel cross-sectional study[J],Journal of Pharmacy and BioalliedSciences,2010,2(2):132-136.
[69]于坤,曹建文,傅华等.影响医生处方行为的因素分析[J],中华医院管理杂志,2002,18(2):92-94.
[70]戴伟辉,柴佳鹏.临床医生处方行为的影响因素分析与实证研究[学位论文],2009.
[71]Flora Haayer.Rational Prescribing and Sources of Information [J], Soc.Sci.Med,1982,16:2017-2023.
[72]Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on theprescribing behavior of physicians[J].Am J Med.1982,73:4-8.
[73]张翠华,贺加.基于医生处方行为的影响因素及约束机制分析[J],中国社会医学杂志,2011,28(4):246-248.
[74]P.Denig et al.Towards understanding treatment preferences of hospital physicians[J],Soc.Sci.Med,1993,36(7):915-924.
[75]Patricia Carthy et al.A study of factors associated with cost and variation in prescribingamong GPs[J],Family Practice,2000,17(1):36-41.
[76]Morten Andersen,Jakob Kragstrup,Jens Sondergaard.How conducting a clinical trialaffects physicians‘guideline adherence and drug preferences[J], JAMA,2006,295(23):2759-2764.
[77]徐凌中.山东省乡村医生国家基本药物制度认知与行为KABP调查分析[J],中国卫生事业管理,2011,(9):691-693.
[78]宁德斌.医生引致需求及其治理,武汉大学学报(哲学社会科学版),2011,64(1):84-90.
[79]Jill Cockburn,Sabrina Pit.Prescribing behaviour in clinical practice:patients‘expectations and doctors‘perceptions of patients expectations-a queationnaire study[J],BMJ,315:520-523.
[80]Teviot S.Eimerl.The pattern of prescribing[J],J.Coll.gen.Practnrs,1962,5:468-479
[81]毛华娟,戴伟辉.医师处方行为分析的研究现状[J],临床合理用药,2011,4(9A):159-160.
[82]Letizia Orzella et al.Physician and patient characteristics associated with prescriptionsand costs of drugs in the Lazio region of Italy[J],Health Policy,2010,95(2-3):236-244.
[83]Stolley PD,Lasagna L.Prescribing patterns of physicians[J],J Chronic Dis,1969,22(6):395-405.
[84]John A.H.Lee,Peter A.Draper,Miles Weatherall.Primary medical care:Prescribing inthree English towns[J],Milbank Mem.Fund.Q.Bull,1965,43:285-290.
[85]Elina Hemminki.Review of literature on the factors affecting drug prescribing[J],Soc.Sci.&Med,1975,9:111-115.
[2]WHO.The selection and use of essential drugs: report of a WHO expercommittee [M].(Tech Rep Ser WHO no.914). Geneva: World Health Organization，2003.
[2]WHO. The rational use of drugs: report. Geneva: World Health Organization,1987.
[4]WHO. WHO Policy Perspectives on Medicines, Series No4-The Selection of EssentialMedicines [M]. Geneva,2002.
[5]WHO. The rational use of drugs: report. Geneva: World Health Organization,1987.
[6]Availability. Wikipedia.24November2012.http://en.wikipedia.org/wiki/Availability.
[7]WHO. Indicators for monitoring national drug policies. A practical manual. Secondedition [M]. Geneva,2000.
[8]WHO. How to investigate drug use in health facilities-----Selected drug useindicators [M]. Action programme on essential drugs.1993.
[9]Eric G Sarriot，Peter J. Winch， Leo J Ryan. A methodological approach and frameworkfor sustainability assessment in NGO-implemented primary health care programs [J]. Int JHealth Planning Mgmt2004;19:23–41.
[10]Eric G Sarriot，Peter J Winch，Leo J Ryan. Qualitative research to make practical senseof sustainability in primary health care projects implemented by non-governmentalorganizations [J]. Int J Health Planning Mgmt2004;19:3–22.
[11]Bossert TJ. Can they get along without us? Sustainability of donor-supported healthprojects in Central America and Africa. Soc Sic med1990,30:1015-1023
[12]Lafond AK.1995. Improving the quality of investment in health: lessons onsustainability. Health Policy Plan10:63–76.
[13]Mona C. Shediac-Rizkallah， Lee R. Bone. Planning for the sustainability ofcommunity-based health programs: conceptual frameworks and future directions forresearch, practice and policy[J]. Health Education Research： Vol.13. no. l1998：87-10.
[14]Alice Yang, Paul E. Farmer, Anita M. Mcgahan. Sustainability‘in global health[J].Global Public Health.2010:5(2):129-135.
[15]Eric G. Sarriot, Peter J. Winch. A methodological approach and framework forsustainability assessment in NGO-implemented primary health care programs. Int J HealthPlann Mgmt2004;19:23–41.
[16]彭静,江启成.基本药物制度利益相关者的界定及分析.中国卫生事业管理.2011（5）：348-360.
[17] Joint Commission International Accreditation Standards for Hospital[M]. JointCommission International. Illinois: Joint Commission Resources.2007.
[18]R Roy Chaudhury, R Parameswar, U Gupta, etc. Quality medicines for the poor:experience of the Delhi programme on rational use of drugs[J].Health Policy andPlanning,2005,20(2):124-136
[19]叶露.国家基本药物政策研究[D].上海：复旦大学,2008.
[20]Susan E Tett. A perspective on Australia‘s National Medicine Policy[J].Can J ClinPharmacol,11(1):e28-e38
[21]武瑞雪，刘宝，丁静芳等.基本药物制度实施的国际经验[J].中国药房,2007,18(17):1283-1285.
[22]Anna Hynd, Elizabeth E.Roughead, David B.Preen, etal. The impact of co-paymentincreases on dispensings of government-subsidized medicines in Australia [J].Pharmacoepidemiology and Drug Safety,2008,17:1091-1099.
[23]谢敬敏，张方.关于国家基本药物目录与―医保‖目录、―新农合‖报销目录衔接的思考[J].中国药房,2011,22(16):1443-1445.
[24]焦婷婷，冯泽永.基本药物配置配送环节影响因素分析及对策[J].中国药房.2012，23(16):1474-1476,
[25]欣越.澳大利亚医院管理[J].中国卫生产业,2006,11:84-86.
[26]梁智.澳大利亚医疗制度与改革[J].《国外医学》卫生经济分册,2006,23(3):97-102.
[27]Delia Hendrie and Duncan Boldy. Hospital services and casemix in WesternAustralia[J]. Australia Health Review,2002,25(1):173-188
[28]Lynn Maria Weekes, Colleen Brooks. Drug and Therapeutics Committee inAustralia: expected and actual performance [J]. Br J Clin Pharmacol,1996,42:551-557.
[29]Thailand a country case study: good governance and preventing corruption.WHO.http://www.who.int/features/2010/medicines_thailand/en/index.html.
[30]杨一帆.实施基本药物制度的问题与对策研究.沈阳：沈阳师范大学，2012
[31]邱凯锋，游思平，邓丽华等.国家基本药物在某二级综合医院的应用研究[J].中国医院用药评价与分析,2011,11(10):890-892.
[32]张强，张继海.我院2009年3月-2010年2月基本药物应用情况调查分析[J].中国药房,2010,21(44):4132-4133.
[33]刘朝杰，李伟，姚岚.澳大利亚的社区卫生服务与全科医疗对中国的影响和蕴义[J].中国全科医学,2004,7(21):1545-1550
[34]A.J.Smith, P.McGettigan. Quality use of medicines in the community: theAustralian experience[J].Br J Clin Pharmacol,2000,50:515-519.
[35]L.M.Weekes, J.M.Mackson, M.Fitzgerald, etal. National Prescribing Service: creatingan implementation arm for national medicines policy [J].British Journal of ClinicalPharmacology,2005,59:112-116.
[36]Constraints on prescribers.http://www.pbs.gov.au/info/about-the-pbs#Constraints_on_prescribers.
[37]What are the restrictions on PBS prescriptions? http://www.pbs.gov.au/info/general/faq.
[38]杨帅.我国基本药物制度实施问题研究[D].南京中医药大学，2011.
[39]刘建美.基于国家基本药物政策的县级医院合理用药现状研究[D].山西医科大学,2011.
[40]邵辉,李士雪,徐凌忠,杨爽.山东省基层医疗机构门诊医生基本药物使用医院影响因素分析[J].中国卫生事业管理,2011(12):904-906.
[41]韩晓亮.基于博弈论的基本药物制度研究[D].黑龙江中医药大学.2010.
[42]What are the current patient fees and charges?http://www.pbs.gov.au/info/about-the-pbs#What_are_the_current_patient_fees_and_charges.
[43]王迪飞.基本药物制度实施中的社会医疗保险干预策略研究[D].华中科技大学，2012.
[44]夏俊，田昕，张新平.基本药物医保报销政策研究[J].医学与社会,2010,23(6):64-66.
[45]WHO/HAI. Measuring medicine prices, av ailability, affordability and pricecomponents2ND EDITION[M]. Switzerland: WHO/HAI,2008:1-181.
[46]Greenhalgh T. Drug prescriptions and self-medication in India, an exploratory survey.Social Science and Medicine.1987(25):307-318.
[47]陈峰,陈光启.医学多元统计分析方法（第二版）[M].北京：中国统计出版社,2007：23.
[48]Wen Chen, Shenglan Tang, Jing Sun. Availability and use of essential medicines inChina: manufacturing, supply, and prescribing in Shandong and Gansu provinces[J]. BMCHealth Services Research.2010,10:211.
[49]Hao Yang, Hassan H Dib, Xinping Zhang. Prices, availability and affordability ofessential medicines in rural areas of Hubei Province, China [J]. Health Policy and Planning.2010;25:219-229.
[50]王思欧,刘洋,管晓东.我国部分地区基本药物价格水平实证研究。中国卫生事业管理.2011（4）：266-268.
[51]叶露,胡善联.上海市基本药物可负担性实证研究[J].中国卫生资源,2008,11(4):195-196.
[52]A Cameron, M Ewen, D Ross-Degnan. Medicine prices, availability, and afordabilityin36developing and middle-income countries: a secondary analysis. Published onlineDecember1,2008DOI:10.1016/S0140-6736(08)61762-6.
[53]Mustafa Z Younis, Samer Hamidi, Dana A Forgione, etal. Rational use effects ofimplementing an essential medicines list in West Bank, Palestinian Territories [J].Pharmacoeconomics Outcomes Res.2009:9(3):243-250.
[54]张新毅，郝瑞东，郝钢.507例门诊处方评价与结果分析[J].中国药物警戒.2010:7（12）:755-757.
[55]龙华,吴红卫,王丹阳等.6000张门诊处方基本指标及合理用药分析[J]. Evaluationand analysis of drug-use in hospitals of China.2009,9(4):280-281.
[56]程海道,陆华,刘滔滔.门诊处方基本指标评价及用药合理性分析[J]. Evaluation andanalysis of drug-use in hospitals of China.2012,12(4):373-375.
[57]Hogerzeil HV, Bimo, Ross-Degnan D, etal. Field tests of rational drug use in twelvedeveloping countries [J]. Lancet1993,4:1408-10.
[58]E. T. Adebayo, N.A. Hussain. Pattern of prescription drug use in Nigerian armyhospitals [J]. Annals of African Medicine.2010:9(3):152-187.
[59]Benjamin Uzochukwu, Obinna Onwujekwe, Cyril Akpala. Effect of theBamako-Initiative drug revolving fund on availability and rational use of essential drugs inprimary health care facilities in south-east Nigeria [J]. Health Policy and Planning;2002:17(4):378-383.
[60]Birna Trap, Ebba Holme Hansen and Hans V Hogerzeil. Prescription habits ofdispensing and non-dispensing doctors in Zimbabwe [J]. Health Policy and Planning;2002:17(3):288-295.
[61]Bounxou Keohavong, Lamphone Syhakhang, Sivong Sengaloundeth,etal. Rational useof drugs: prescribing and dispensing practices at public health facilities in Lao PDR [J].Pharmacoepidemiology and Drug Safety.2006:15:344-347.
[62]K.A. Bashrahil. Indicators of rational drug use and health services in Hadramout,Yemen [J]. Eastern Mediterranean Health Journal.2010,16(2):151-155.
[63]Yacoub M. Irshaid, Mohammed A. Al-Homrany, Anwar A. Hamdi, etal. APharmacoepidemiological study of prescription pattern in outpatient clinics inSouthwestern Saudi Arabia [J]. Saudi Med J2004;25(12):1864-1870.
[64]WHO. Action Programme on Essential Drugs. How to investigate drug use in healthfacilities. World Health Organization, Geneva:1993.1-87.
[65]Flora Haayer. Rational Prescribing and Sources of Information [J], Soc. Sci. Med,1982,16:2017-2023.
[66]Letizia Orzella etal. Physician and patient characteristics associated with prescriptionsand costs of drugs in the Lazio region of Italy [J], Health Policy,2010,95(2-3):236-244.
[67]A. Vallano. E. Montane′. J. M. Arnau.X, Vidal C. Pallares. M. Coll. J. R. Laporte.Medical speciality and pattern of medicines prescription [J]. Eur J Clin Pharmacol (2004)60:725–730.
[68]WHO Policy Perspectives on Medicines. Promoting rational use of medicines: corecomponents, Geneva: WHO;2002.
[69]Hans V Hogerzeil. Promoting rational prescribing: an international perspective [J], Br JPharmac,1995,39:1-6.
[70]Adolfo Figueiras, Isabel Sastre, Juan Jesus Gestal-Otero. Effectiveness of educationalinterventions on the improvement of drug prescription in primary care: a critical literaturereview [J]. Journal of Evaluation in Clinical Practice,2001,7(2):223-241.
[71]于坤,曹建文,傅华等.影响医生处方行为的因素分析[J],中华医院管理杂志,2002,18(2):92-94.
[72]Andersen M,Kragstrup J,Sondergaard J. How conducting a clinical trial affectsphysicians‘guideline adherence and drug preferences [J]. JAMA,2006,295(23):2759-2764.
[73]Melville A. Job satisfaction in General Practice: implications for prescribing. Sot SciMed.1980;4A.495.
[74] Australian Government Department of Health and Ageing. Constraints onprescribers.http://www.pbs.gov.au/info/about-the-pbs#Constraints_on_prescribers
[75]张盛国.完善基本药物制度财政补偿机制[J].中国财政.2010,20:49-50.
[76]WHO/UNICEF. Primary health care: report of the International Conference on PrimaryHealth Care, Alma-Alta, USSR, Sept6–12,1978. Health for all, series1. Geneva: WorldHealth Organization,1978.
[1]Quick J D, Hogerzeil H V, Velasquez G, etal. Perspectives: Twenty-five years ofessential medicines [N]. Bulletin of the World Health Organization,2002,80(11):913-914.
[2]WHO.The selection and use of essential drugs: report of a WHO expertcommittee [M].(Tech Rep Ser WHO no.914). Geneva: World Health Organization，2003.
[3]WHO. The rational use of drugs: report. Geneva: World Health Organization,1987.
[4]WHO. WHO Policy Perspectives on Medicines, Series No4-The Selection ofEssential Medicines [M]. Geneva,2002.
[5]WHO. The selection of essential drugs: report of a WHO expert committee.(TechRep Ser WHO no615). Geneva: World Health Organization,1977.
[6]WHO.WHO Policy Perspectives on Medicines, Series No8-Equitable access toessential medicines: a framework for collective action [M]. Geneva,2004.
[7]WHO. WHO Model list of essential medicines (17thlist). March2011.http://www.who.int/medicines/publications/essentialmedicines/en/index.html
[8]WHO. WHO Model list of essential medicines for children (3thlist). March2011.http://www.who.int/medicines/publications/essentialmedicines/en/index.html
[9]WHO.The selection and use of essential drugs: report of a WHO expert committee[M].(Tech Rep Ser WHO no950).Geneva: World Health Organization，2008
[10]WHO. How to develop and implement a national drug policy—second edition.[M]. Geneva,2001.
[11]WHO. Indicators for monitoring national drug policies. A practical manual.Second edition [M]. Geneva,2000.
[12]WHO. Operational package for assessing monitoring and evaluating countrypharmaceutical situations[M]. Geneva,2007.
[13]WHO. Action Programme on Essential Drugs. How to investigate drug use inhealth facilities—selected drug use indicators[M]. WHO/DAP/INRUD.1993.
[14]WHO/HAI. Medicine prices a new approach to measurement,2003edition.Working draft for field testing and revision[M]. WHO/EDM/PAR/2003.2.
[15]WHO/HAI. Measuring medicine prices, availability, affordablity and pricecomoonents,2NDedition[M]. WHO/PSM/PAR/2008.3.
[16]Cha-oncin Sooksriwong, Worasuda Yoongthong, Siriwat Suwattanapreeda.Medicine prices in Thailand: A result of no medicine pricing policy[J]. Southern MedReview,2009,2(2):10-14.
[17]Babar ZUD, Ibrahim MIM, Singh H. Evaluating drug prices, availability,affordablity and price comoonents: implication for access to drugs in Malaysia.[O/L].2010-08-09.http://www.plos medicine.Org/article/info:doi/10.1371/journal.pmed.0040082.
[18]HaoYang, HassanHDib, MinminZhu. Prices, availability and affordability ofessential medicines in rural areas of Hubei Province, China. Health Policy andPlanning2010,25:219-229.
[19]叶露,胡善联等.上海药品价格水平实证研究[J].中国卫生资源，2008，1（5）：238-240.
[20]A Cameron, M Ewen, D Ross-Degnan. Medicine prices, availability, andaffordability in36developing and middle-income countries: a secondary analysis[O/L].2010-08-09. http//:www.ncbi.nlm.nih.gov/pubmed/19042012.
[21]Douglas Ball. Review Series on Pharmaceutical Pricing Policies andInterventions: Working Paper3: The Regulation of Mark-ups in the PharmaceuticalSupply Chain[M]. WHO/HAI Project on Medicine Prices and Availability. May2011.
[22]Laing R Waning B, Gray A.25years of the WHO essential medicines lists:progress and challenges [J]. Lancet,2003,361(9370):1723-9
[23]MarcusMReidenberg,TomWalley. Commentary: The pros and cons of essentialmedicines for rich countries[J]. BMJ VOLUME32913NOVEMBER2004:1172.
[24]HansVHogerzeil. The concept of essential medicines: lessons for richcountries[J]. BMJ VOLUME32913NOVEMBER2004：1169-1172
[25]Zafar Mirza. Thirty years of essential medicines in primary health care[J].Eastern Mediterranean Health Journal, Vol.14, Special Issue:74-81.
[26]Djékadoum Ndilta. Medicines and Primary health care: challenges and hopes inthe church health systems[J]. Contact n°187–January-May2009:8-13.
[27]Jane Masiga. Medicines and Primary health care: where are we?[J]. Contactn°187–January-May2009:14-17.
[28]孙静. WHO基本药物概念与国家实践[J]. Chinese Journal of Health Policy,January2009, Vol.2No.1:38-46.
[29]武瑞雪,刘宝,丁敬芳.基本药物制度实施的国际经验[J].中国药房.2007:17（18）：1283-1285.
[30]胡善联,张崖冰,叶露.国家基本药物制度研究[J].卫生经济研究.2007，10:3-5.
[31]覃正碧,汪志宏,谭刚等.国家基本药物制度的现状及其完善对策探讨[J].中国药房，2008，19(14):1041-1043.
[32]李锋.关于构建国家基本药物制度的若干思考[J].中国卫生事业管理.2010（7）：456-458.
[33]王强.基本药物流通价值链的经济学研究[D].复旦大学：2010年
[34]李红梅.基本药物制度符合百姓利益，需改变以药养医现象[J].人民网-《人民日报》.2011-11-07. http://health.people.com.cn/GB/16157006.html.
[35]Availability. Wikipedia.24November2012.http://en.wikipedia.org/wiki/Availability
[36]WHO. Indicators for monitoring national drug policies. A practical manual. Secondedition [M]. Geneva,2000.
[37]Quick JD (2003) Essential medicines twenty-fve years on: closing the access gap[J].Health Policy&Planning18,1–3.
[38]Access to Essential Drugs in2Brazilian Cities: A Community-based Evaluation.Marg Gomes de Oliveira Karnikowski; Otávio de Toledo Nóbrega; Janeth de Oliv. Journalof Public Health Policy;2004;25,288-298.
[39]Kotwani A, Ewen M, Dey D et al.(2007) Prices&availability of common medicines atsix sites in India using a standard methodology[J]. Indian Journal of Medical Research125,645.
[40]Saleh K&Ibrahim MI (2005) Are essential medicines in Malaysia accessible,affordable and available[J]? Pharmacy World&Science27,442–446.
[41]Babar ZU, Ibrahim MI, Singh H, Bukahri NI&Creese A (2007) Evaluating drug prices,availability, affordability, and price components: implications for access to drugs inMalaysia[J]. PLoS Medicine Public Library of Science4, e82.
[42]Adbol Majid Cheraghali. Availability, Affordability and prescribing pattern ofmedicines in Sudan. Pharmacy World Science.2009,31:209-215.
[43]Mendis S, Fukino K, Cameron A et al.(2007) The availability and affordability ofselected essential medicines for chronic diseases in six low-and middle-incomecountries[J]. Bulletin of the World Health Organization85,279–288.
[44]Sun Qiang，A Survey of Medicine Prices, Availability, Affordability and PriceComponents in Shandong Province, China， October,2005[O/L].[2010-08-09].http://www.haiweb.org/medicineprices/surveys.php.
[45]Hao Yang, Hassan H Dib, Minmin Zhu. Prices, availability and affordability ofessential medicines in rural areas of Hubei Province, China [J]. Health Policy and Planning2010;25:219–229.
[46]Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio. Access to essential drugs inGuyana: a public health challenge. International Journal of Health Planning andManagement.2010,25:2–16.
[47]Lloyd Matowe. Access to essential drugs in developing countries: A lost battle?American Journal of Health System Pharmacy2004,61:718-721
[48]Michael Nunan，Trevor Duke. Effectiveness of pharmacy interventions in improvingavailability of essential medicines at the primary healthcare level. Tropical Medicine andInternational Health.2011,16:647-658.
[49]Michael Nunan，Trevor Duke. Effectiveness of pharmacy interventions in improvingavailability of essential medicines at the primary healthcare level[J]. Tropical Medicine andInternational Health. volume16no5pp647–658may2011.
[50]李萍，张新平.改善农村地区基本药物可获得性策略研究.华中科技大学.2009.
[51]刘宝,武瑞雪,叶露.论基本药物的可获得性和可及性障碍[J].中国药房.2007,5:1-6.
[52]王力,余苏珍,王素珍.提高我国基本药物可及性的政策措施研究.中国卫生经济.2011，7（30）：25-26.
[53]Benjamn SC Uzochukwn. Effect of the Bamako-Initiative drug revolving fund onavailability and rational use of essential drugs in primary health care facilities in South-eastNigeria. Health policy and Planning.2002,17(4):378-383.
[54]W W Anokbonggo，J W Ogwal-Okeng. Imapct of decentralization on heslth services inUganda: A look at facility utilization, prescribing and availability of essential drugs. EastAfrican Medical Journal.2004,81:2-7.
[55]WHO. Harvard Medical School. Medicine use in primary Care in developing andtransitional countries [M].WHO/EMP/MAR.2009:1.
[56]WHO. Promoting rational use of medicines: core components. WHO PolicyPerspectives on Medicines. Sep.2002.
[57]WHO.基本药物概念与实践-向中国政府提交的政策说明[M].国际合理用药与WHO公报汇编,北京：中国科技出版社,2009:50.
[58]姚岚等.合理用药的国际研究进展[J],中国初级卫生保健,2002,16(3):4-6.
[59]Hans V Hogerzeil.Promoting rational prescribing:an international perspective[J],Br JPharmac,1995,39:1-6.
[60]王跃平等.深圳市福田区社康中心基本药物的配备及使用情况分析[J],中国全科医学,2011,14(7A):2188-2191.
[61]祁金文,马珂,陈农.规范医生处方行为提高合理用药水平[J],中华医院管理杂志,2006,22(12):817-819.
[62]刘玉聪,孙利华,孙倩.国外规范医生处方行为的措施及其对我国的启示[J],中国药业,2010,19(24):9-10.
[63]WHO Policy Perspectives on Medicines.Promoting rational use of medicines:corecomponents,Geneva:WHO;2002.
[64]R Mahajan,NR Singh,J Singh et al.Assessment of Awareness among Clinicians aboutConcepts in Undergraduate Pharmacology Curriculum: A Novel Cross-sectional Study[J],Journal of Young Pharmacists,2010,2(3):301-305.
[65]曾雁冰,杨世民.对基本药物认知及临床应用情况的调查研究[J],中国药事,2008,22(9):756-762.
[66]Geoffrey M.Anderson,Joel Lexchin,Strategies for Improving Prescribing Pratice[J],Can Med Assoc J,1996,154(7):1013-1017.
[67]Adolfo Figueiras,Isabel Sastre,Juan Jesus Gestal-Otero.Effectiveness of educationalinterventions on the improvement of drug prescription in primary care:a critical literaturereview,Journal of Evaluation in Clinacal Practice,2001,7(2):223-241.
[68]Rajiv Mahajan et al.Current scenario of attitude and knowledge of physicians aboutrational prescription: A novel cross-sectional study[J],Journal of Pharmacy and BioalliedSciences,2010,2(2):132-136.
[69]于坤,曹建文,傅华等.影响医生处方行为的因素分析[J],中华医院管理杂志,2002,18(2):92-94.
[70]戴伟辉,柴佳鹏.临床医生处方行为的影响因素分析与实证研究[学位论文],2009.
[71]Flora Haayer.Rational Prescribing and Sources of Information [J], Soc.Sci.Med,1982,16:2017-2023.
[72]Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on theprescribing behavior of physicians[J].Am J Med.1982,73:4-8.
[73]张翠华,贺加.基于医生处方行为的影响因素及约束机制分析[J],中国社会医学杂志,2011,28(4):246-248.
[74]P.Denig et al.Towards understanding treatment preferences of hospital physicians[J],Soc.Sci.Med,1993,36(7):915-924.
[75]Patricia Carthy et al.A study of factors associated with cost and variation in prescribingamong GPs[J],Family Practice,2000,17(1):36-41.
[76]Morten Andersen,Jakob Kragstrup,Jens Sondergaard.How conducting a clinical trialaffects physicians‘guideline adherence and drug preferences[J], JAMA,2006,295(23):2759-2764.
[77]徐凌中.山东省乡村医生国家基本药物制度认知与行为KABP调查分析[J],中国卫生事业管理,2011,(9):691-693.
[78]宁德斌.医生引致需求及其治理,武汉大学学报(哲学社会科学版),2011,64(1):84-90.
[79]Jill Cockburn,Sabrina Pit.Prescribing behaviour in clinical practice:patients‘expectations and doctors‘perceptions of patients expectations-a queationnaire study[J],BMJ,315:520-523.
[80]Teviot S.Eimerl.The pattern of prescribing[J],J.Coll.gen.Practnrs,1962,5:468-479
[81]毛华娟,戴伟辉.医师处方行为分析的研究现状[J],临床合理用药,2011,4(9A):159-160.
[82]Letizia Orzella et al.Physician and patient characteristics associated with prescriptionsand costs of drugs in the Lazio region of Italy[J],Health Policy,2010,95(2-3):236-244.
[83]Stolley PD,Lasagna L.Prescribing patterns of physicians[J],J Chronic Dis,1969,22(6):395-405.
[84]John A.H.Lee,Peter A.Draper,Miles Weatherall.Primary medical care:Prescribing inthree English towns[J],Milbank Mem.Fund.Q.Bull,1965,43:285-290.
[85]Elina Hemminki.Review of literature on the factors affecting drug prescribing[J],Soc.Sci.&Med,1975,9:111-115.